Buy Rating for Precision BioSciences: Promising ARCUS-Based Programs and Strong Gene Editing Prospects

Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Precision BioSciences (DTIL – Research Report) and keeping the price target at $60.00.

Patrick Trucchio has given his Buy rating due to a combination of factors including the promising progress of Precision BioSciences’ ARCUS-based programs. The company is making significant strides with its PBGENE-DMD program for Duchenne muscular dystrophy (DMD) and the Phase 1 ELIMINATE-B trial for chronic hepatitis B virus infection. These advancements, supported by partner-led clinical validation, highlight the potential of Precision’s gene editing platform.
Additionally, the PBGENE-DMD program shows compelling preclinical data, demonstrating durable dystrophin restoration and functional muscle improvement. This program is designed to address a significant portion of the DMD population by removing specific gene exons, offering a potential one-time intervention with broad muscle engagement. The ARCUS platform’s ability to deliver dual nucleases via a single AAV distinguishes it from other gene editing technologies, positioning Precision BioSciences well within the competitive landscape. With a solid cash runway and a validated platform, the company is poised to achieve multiple in vivo gene editing milestones in the near term.

In another report released on May 16, JonesTrading also maintained a Buy rating on the stock with a $30.00 price target.